Log in to your Inderes Free account to see all free content on this page.

Nanexa

3.55 SEK

-0.98 %

Less than 1K followers

NANEXA

First North Stockholm

Biotechnology & Pharmaceuticals

Health Care

Overview

Financials & Estimates

Ownership

Dividend

Investor consensus

-0.98 %

-4.31 %

-7.67 %

-20.22 %

+110.06 %

+84.32 %

+17.16 %

-58.10 %

-56.61 %

Nanexa is a drug delivery company with a proprietary platform used for the formulation of injectable depot drugs that create a supply of drugs to the blood. The company's technology is based on encapsulating drug particles with a thin shell and creating opportunities for pharmaceutical companies to develop new products. Nanexa has collaborations with several pharmaceutical companies, mainly around the Nordic market.

Market cap

678.18M SEK

Turnover

191.02K SEK

Revenue

EBIT %

P/E

Dividend yield-%

Revenue and EBIT-%

Revenue M

EBIT-% (adj.)

EPS and dividend

EPS (adj.)

Dividend %

Financial calendar

27.8.

2026

Interim report Q2'26

5.11.

2026

Interim report Q3'26

All

Press releases

3rd party

ShowingAll content types

Regulatory press release5/12/2026, 3:00 PM

Bulletin from the Annual General Meeting of Nanexa AB

Third party research4/30/2026, 6:22 AM

Nanexa: Strong semaglutide data and reinforced funding extend strategic runway - Emergers

Following the license agreement with Moderna in Q4’25, Nanexa continues to advance along three parallel value tracks: the Moderna collaboration, additional PharmaShell license deals and the internally developed long-acting semaglutide program. Q1’26 ...

Regulatory press release4/29/2026, 6:00 AM

Nanexa publishes interim report for January-March 2026

Join Inderes community

Don't miss out - create an account and get all the possible benefits

FREE account

Stock market's most popular morning newsletter

Analyst comments and recommendations

Stock comparison tool

PREMIUM account

All company reports and content

Premium tools (e.g. insider transactions & stock screener)

Model portfolio

Regulatory press release4/28/2026, 4:55 PM

Nanexa resolves on set-off of outstanding loan

Regulatory press release4/8/2026, 6:01 AM

Notice of annual general meeting in Nanexa AB (publ)

Press release4/2/2026, 6:00 AM

Nanexa announces exercise of warrants

Regulatory press release3/26/2026, 7:01 AM

Nanexa publishes annual report for 2025

Press release3/19/2026, 7:59 AM

Nanexa Demonstrates Feasibility of Quarterly Semaglutide Dosing with PharmaShell®

Press release2/24/2026, 7:15 AM

Nomination Committee for the 2026 Annual General Meeting in Nanexa AB (publ)

Third party research2/20/2026, 7:41 AM

Nanexa: Funding secured as semaglutide pivot sharpens commercial focus - Emergers

Following the breakthrough license deal with Moderna, a global leader in mRNA therapeutics, in Q4’25, Nanexa now pursues two main tracks to leverage its PharmaShell technology into commercial value creation: the Moderna license development agreement ...

Regulatory press release2/19/2026, 7:01 AM

Nanexa publishes year-end report and Q4 report 2025

Regulatory press release1/27/2026, 7:30 AM

Nanexa Announces Breakthrough Preclinical Data Demonstrating Exceptional Pharmacokinetic Profile for Monthly Semaglutide Formulation

Third party research12/12/2025, 7:12 AM

Nanexa: First license with Moderna an important validation of PharmaShell - Emergers

The announcement of Nanexa’s first licensing deal marks a meaningful validation of the PharmaShell platform, as Moderna, a global leader in mRNA therapeutics, commits to test up to five compounds under a structure including USD 3m upfront, up to USD ...

Press release12/12/2025, 7:00 AM

Emergers: Equity Research | NANEXA: First license with Moderna an important validation of PharmaShell

Regulatory press release12/10/2025, 9:35 PM

Nanexa and Moderna enter into license and option agreement for the development of PharmaShell®-based products

Third party research11/7/2025, 8:58 AM

Nanexa: Intensified focus on deals amid growing funding pressure - Emergers

Nanexa’s Q3 report underscores a pivotal moment for the company. While interest in its PharmaShell technology remains strong, with advanced business discussions ongoing and an extended evaluation agreement in a multi-billion-dollar indication, the financial...

Press release11/7/2025, 7:00 AM

Emergers: Equity Research | NANEXA: Intensified focus on deals amid growing funding pressure

Regulatory press release11/6/2025, 7:00 AM

Nanexa publishes interim report for January-September 2025

Press release10/16/2025, 6:25 AM

Nanexa named as finalist in Fierce Innovation Awards Life Sciences Edition 2025

Regulatory press release10/1/2025, 10:40 AM

Nanexa AB changes Certified Adviser to Tapper Partners AB

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.